Tiansheng Pharmaceutical Group Co., Ltd. (SHE:002872)
China · Delayed Price · Currency is CNY 6.03
+0.08 (1.34%)
Sep 2, 2026, 3:04 PM CST
SHE:002872 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 1,892 | 1,545 | 1,444 | 1,631 | 1,679 | 1,660 | |
Market Cap Growth | 23.19% | 7.05% | -11.50% | -2.84% | 1.15% | 10.13% |
Enterprise Value | 1,953 | 1,673 | 1,600 | 1,714 | 1,849 | 1,903 |
Last Close Price | 5.95 | 4.86 | 4.54 | 5.13 | 5.28 | 5.22 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PS Ratio | 3.67 | 3.01 | 2.53 | 2.82 | 2.77 | 2.25 |
PB Ratio | 0.98 | 0.79 | 0.72 | 0.78 | 0.77 | 0.73 |
P/TBV Ratio | 1.13 | 0.91 | 0.84 | 0.92 | 0.90 | 0.85 |
P/FCF Ratio | 58.20 | 96.28 | - | - | 106.52 | - |
P/OCF Ratio | 30.53 | 35.97 | 28.79 | - | 18.83 | 87.50 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.79 | 3.26 | 2.81 | 2.96 | 3.05 | 2.58 |
EV/EBITDA Ratio | 30.98 | 26.10 | 34.27 | 94.15 | 155.97 | 127.58 |
EV/FCF Ratio | 60.08 | 104.24 | - | - | 117.29 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.17 | 0.18 | 0.18 | 0.16 | 0.15 | 0.18 |
Debt / EBITDA Ratio | 5.20 | 5.51 | 7.65 | 15.28 | 23.39 | 23.57 |
Debt / FCF Ratio | 9.99 | 22.39 | - | - | 20.88 | - |
Net Debt / Equity Ratio | 0.03 | 0.04 | 0.05 | 0.06 | 0.02 | 0.00 |
Net Debt / EBITDA Ratio | 0.93 | 1.23 | 2.08 | 7.30 | 4.30 | -0.46 |
Net Debt / FCF Ratio | 1.66 | 4.92 | -773.18 | -1.31 | 3.23 | 0.07 |
Asset Turnover | 0.20 | 0.19 | 0.21 | 0.20 | 0.20 | 0.22 |
Inventory Turnover | 2.75 | 2.64 | 2.54 | 2.41 | 2.19 | 2.14 |
Quick Ratio | 1.12 | 1.37 | 1.64 | 1.20 | 1.19 | 1.57 |
Current Ratio | 1.35 | 1.64 | 1.96 | 1.52 | 1.47 | 1.95 |
Return on Equity (ROE) | -2.23% | -2.82% | -4.29% | -4.38% | -4.10% | -3.10% |
Return on Assets (ROA) | -1.49% | -1.28% | -1.36% | -1.86% | -1.92% | -1.34% |
Return on Invested Capital (ROIC) | -3.08% | -2.66% | -2.79% | -3.85% | -4.15% | -2.95% |
Return on Capital Employed (ROCE) | -3.00% | -2.50% | -2.50% | -3.60% | -3.90% | -2.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -2.27% | -3.59% | -6.05% | -5.71% | -5.39% | -4.08% |
FCF Yield | 1.72% | 1.04% | -0.01% | -6.21% | 0.94% | -5.75% |
Buyback Yield / Dilution | 0.04% | -0.01% | 0.01% | 0.00% | 0.01% | -0.01% |
Total Shareholder Return | 0.04% | -0.01% | 0.01% | 0.00% | 0.01% | -0.01% |